Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 12/20 | 0.60 |
| ▸ | EGFR | P00533 | 10/20 | 0.60 |
| ▸ | KIT | P10721 | 2/20 | 0.58 |
| ▸ | ABL1 | P00519 | 6/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | FLT3 | P36888 | 1/20 | 0.57 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | BCR | P11274 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31060809 | 0.95 | BRAF (0.59) | BRAFEGFRKITABL1FGFR1 | |
| SCHEMBL15859828 | 0.95 | BRAF (0.59) | BRAFEGFRKITABL1FGFR1 | |
| SCHEMBL15859803 | 0.94 | BRAF (0.59) | BRAFEGFRKITABL1FGFR1 | |
| SCHEMBL15859903 | 0.94 | EGFR (0.60) | BRAFEGFRKITABL1FGFR1 | |
| SCHEMBL15859862 | 0.93 | ABL1 (0.55) | BRAFEGFRKITABL1FGFR1 | |
| SCHEMBL15859829 | 0.93 | BRAF (0.57) | BRAFEGFRKITABL1FGFR1 | |
| SCHEMBL17311263 | 0.93 | BRAF (0.57) | BRAFEGFRKITABL1FGFR1 | |
| SCHEMBL17311270 | 0.91 | EGFR (0.55) | BRAFEGFRKITABL1FGFR1 | |
| SCHEMBL15859840 | 0.91 | BRAF (0.61) | BRAFEGFRKITABL1FGFR1 | |
| SCHEMBL15859869 | 0.91 | KIT (0.53) | BRAFEGFRKITABL1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403823-B2 | Protein kinase inhibitors | ORIBASE PHARMA (FR) | 2016-08-02 | — | — | US | disclosed |
| US-9403823-B2 | Protein kinase inhibitors | ORIBASE PHARMA (FR) | 2016-08-02 | — | — | US | disclosed |
| US-20160009709-A1 | PROTEIN KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2016-01-14 | — | — | US | disclosed |
| US-20160009709-A1 | PROTEIN KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2016-01-14 | — | — | US | disclosed |
| WO-2014102376-A1 | PROTEIN KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2014-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009709-A1 | PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K2 | BRAF 32/4885EGFR 738/4885KIT 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.